AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 91 min read$HALO

Torley Helen sold $153K of HALO

Torley Helen (PRESIDENT AND CEO) sold 1,923 shares of HALOZYME THERAPEUTICS, INC. (HALO) at an average of $79.77 ($79.28–$80.19, $0.15M total) across 2 trades on 2026-07-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Torley Helen
Published Jul 9, 2026, 9:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HALO
Neutral
high confidence
Mentioned
$HALO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HALONeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but without new company fundamentals, the practical trading impact is typically small.

02

Market read

A routine 10b5-1 insider sale is disclosed; it is more relevant for sentiment tracking than for a fresh fundamental thesis.

03

What to watch

The article does not state whether additional insider sales occurred around the same period, nor does it provide context on total insider holdings changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: after-hours, following the July 9 SEC Form 4 filing

Background

The article is an SEC Form 4 insider transaction disclosure for Halozyme Therapeutics, Inc., filed July 9, covering a CEO open-market sale on July 8 under a 10b5-1 plan.

Company-level read

Ticker impact

$HALONeutralHigh confidence
Context

SEC Form 4 shows HALO CEO Torley Helen sold about 1,923 shares in an open-market sale under a 10b5-1 plan on July 8.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to intraday sentiment around insider selling.

Evidence & confidence

The filing is a routine Form 4 open-market sale with a pre-arranged 10b5-1 plan, and the article provides no accompanying operational, financial, or regulatory development.

Market effects

Sector

No clear sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, limiting interpretive value.

Key entities

  • issuer
    HALO

    Halozyme Therapeutics, Inc., the company whose CEO insider sale is disclosed.

  • insider
    Torley Helen

    President and CEO of Halozyme Therapeutics, reported as the seller in the Form 4.

Read at source← All news

Related articles

AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min
AUG 7
$HALOHighAI 9/10

Halozyme climbs after record Q2 results and higher 2026 outlook

Halozyme Therapeutics (HALO) shares rose about 15% after the company reported record Q2 2026 results and raised 2026 guidance, according to Halozyme’s investor release. Q2 total revenue increased 48% to $481 million, royalty revenue rose 50% to $307.7 million. Full-year 2026 revenue guidance was raised to $1.835B-$1.910B and non-GAAP diluted EPS to $8.65-$9.00.

quiverquant.com4 min
AUG 7
$HALOHighAI 9/10

Why is Halozyme Therapeutics stock surging today?

Halozyme Therapeutics shares rose about 6.1% pre-open after the company reported record Q2 2026 results. Total revenue increased 48% to $481 million and non-GAAP EPS was $2.28, both above expectations. Royalty revenue hit $307.7 million. Halozyme raised full-year 2026 guidance to non-GAAP EPS of $8.65-$9.00 and revenue of $1.835-$1.910 billion, and said it signed five new ENHANZE/Hypercon deals year-to-date.

investing.com2 min
AUG 7
$HALOMedAI 8/10

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) reported Q2 royalty momentum for VYVGART Hytrulo, with royalty revenue up 143% to $72.6M and total VYVGART brand sales up 60% to $1.5B. Other royalty revenue rose 85% to $54.4M. Halozyme raised 2026 guidance to $1.835B-$1.91B revenue and $8.65-$9.00 non-GAAP EPS, and repurchased $332.8M of stock.

yahoo.com6 min